Agomelatine


1. Productinformatie agomelatine (Valdoxan®), via: www.ema.europa.eu, human medicines, EPAR’s.
2. CFH-rapport agomelatine (Valdoxan®), via: www.cvz.nl, CFH-rapporten.
3. Lemoine P, et al. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxin. J Clin Psychiatry 2007; 68: 1723-1732.
4. Kennedy SH, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-333.
5. Montgomery SA, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280.
6. Agomelatine. Adverse effects and no proven efficacy. Prescrire Int 2009; 18: 241-245. 7. Agomelatin (Valdoxan) bei Depression. Arznei-telegramm 2009; 40: 43-44.

                                                            

Auteurs

  • dr D. Bijl